New Jersey is the birthplace and home of many people who have gone on to achieve fame and success. Here are some examples.
In his CEO Commentary, Frederic Revah, Ph.D., underscores the dedication, expertise and successes of Genethon's 240 scientists and professional staff as they pursue new gene therapy treatments for ...
Genethon, a non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), began the new year with an R&D licensing deal for its gene therapy approach to ...
Disability advocate TaLisha Gryzb is a mother of four living with muscular dystrophy who educates viewers about her ...
New York, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) is proud to announce the recipients of the 2026 MDA Legacy Awards, recognizing excellence in scientific and ...
JACKSONVILLE, Fla., Dec. 17, 2025 /PRNewswire/ -- Acosta Group and the Muscular Dystrophy Association (MDA) are proudly celebrating 40 years of partnership dedicated to empowering people living with ...
JACKSON, MI – A Jackson-area firefighter union’s participation in the annual “Fill the Boot” charity drive has once again successfully collected a sizable amount of donations from the community. The ...
New York, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the awarding of seven new collaborative research grants totaling nearly $2 million to advance ...
Celebrity hairstylist Ken Paves has collaborated with MDA, the Muscular Dystrophy Association, to launch The Helen Paves Fund for Care and a Cure. The $5 million campaign will “support global research ...
New York, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), developed ...
New York, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), developed ...